DermaSensor Product Brochure
Better decisions, better detection, more accurate management DermaSensor empowers physicians by providing objective, actionable risk results to aid in skin cancer detection by assessing cellular and sub-cellular features that cannot be seen visually or dermoscopically.
Features
- Handheld, portable design
- Non-invasive optical spectroscopy
- Beneath the skin, cellular-level analysis
- Immediate objective results
- AI-powered, ultra-miniaturized ESS technology
Indications for use
The DermaSensor™ device is indicated for evaluating skin lesions suggestive of melanoma, basal cell carcinoma, and/or squamous cell carcinoma in patients aged 40 and above, to assist in the decision to refer the patient to a dermatologist.
The DermaSensor device should be used in conjunction with the totality of clinically relevant information from the clinical assessment, including visual analysis of the lesion, by physicians who are not dermatologists. The device should be used on lesions already assessed as suspicious for skin cancer and not as a screening tool.
The device should not be used as the sole diagnostic criterion nor to confirm clinical diagnosis of skin cancer.
An automated, AI-powered lesion assessment in seconds
AI-powered spectroscopy technology
Xenon lamp pulses light to take ~1mm3 optical tissue samples of cellular features.
The device analyses spectral data across 47 wavelengths for malignancy risk.
The 0-10 output corresponded to a cancer likelihood of 3% (0) to 61% (10)1.
The only FDA Breakthrough skin cancer detection device designed for PCPs Unlisted CPT code options to consider for DermaSensor™ services
| CPT CODE | DESCRIPTOR | APC | APC PAYMENT | RW** |
| 96999 | Unlisted special dermatological service or procedure | 5051 | $198.70 | 2.2284 |
| 17999 | Unlisted procedure; skin, mucuous membrane and subcutaneous tissue | 5051 | $198.70 | 2.2284 |
CPT copyright 2025 American Medical Association for documents distributed in 2026. All rights reserved. CPT is a registered trademark of the American Medical Association.
Disclaimer – The coding and reimbursement information provided in this document is derived from the American Medical Association’s Current Procedural Technology (CPT) as well as the Centers for Medicare and Medicaid Services’ (CMS) website and copyrighted code sets, 2022. All ICD-10-CM, ICD-10-PCS, CPT, and HCPCS codes referenced herein are for informational purposes only. It is the responsibility of the rendering provider to determine and report appropriate codes, modifiers, and charges for health care services rendered to patients in their care. DermaSensor cannot promise or guarantee that a provider’s selection of the codes identified herein are appropriate for a particular procedure or will result in reimbursement from any third party payer. Questions related to specific coding and coverage policies should be directed to the applicable third party payer.
References:
1 Merry SP, Croghan IT, Dukes KA, et al. Primary Care Physician Use of Elastic Scattering Spectroscopy on Skin Lesions Suggestive of Skin Cancer. Journal of Primary Care & Community
Health. 2025;16. doi:10.1177/21501319251344423
2 Seiverling EV, et al. Clinical Utility of an Elastic Scattering Spectroscopy Device in Assisting Primary Care Physicians’ Detection of Skin Cancers. Poster Presentation, Maui Derm Hawaii
Conference, Wailea, HI, January 24-28, 2023.
3 Ferris LK, Jaklitsch E, Seiverling EV, et al. DERM-SUCCESS FDA Pivotal Study: A Multi-Reader Multi-Case Evaluation of Primary Care Physicians’ Skin Cancer Detection Using AI-Enabled
Elastic Scattering Spectroscopy. J Prim Care Community Health. 2025;16:21501319251342106. doi:10.1177/21501319251342106
4 Hartman RI et al., JAAD International (2023), doi: 10.1016/j.jdin.2023.10.0.
5 Seiverling, E.V. (2025). JCAD MRMC Study. Journal of Clinical and Aesthetic Dermatology, October 2025, 58–65. Link
6 Jaklitsch, E., Chang, S., Bruno, S., D’Angelo, N., Tung, J.K., Ferris, L.K. (2025). Prospective evaluation of an AI-enabled ESS device for triage of patient-identified skin lesions in dermatology
clinics. JAAD International, Dec 2025. Mendeley Supplementary Data
DermaSensor Inc. is a medical device company that enables healthcare professionals to effectively check for skin cancer by leveraging cuttingedge technologies. The DermaSensor™ device is a cost effective handheld tool that uses artificial intelligence and spectroscopy to non-invasively test skin lesions for skin cancer risk in seconds. By enabling quick and effective skin cancer checks, DermaSensor ultimately hopes to improve skin cancer detection and save lives. DermaSensor is currently FDA Cleared, and is available for sale in the U.S.
